Clinical Trial · NCT02037945

18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases

Overview

The main purpose of this study is to determine the distribution of 18F Fluorocholine (18F-FCH) in the brain which can help distinguishing radiation-induced scarring from tumor regrowth. In addition, the study will measure levels of 18F-FCH in the blood and (if applicable) in the brain lesion tissue that is removed as part of the planned brain surgery.

Sponsor

Memorial Sloan Kettering Cancer Center

Phase

N/A

Contacts

Kathryn Beal, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02037945

Drug / Compound

Fluorocholine

Isotope(s):
Target(s):
  • Phospholipid Metabolism
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Evolving brain lesions post SRS requiring neurosurgical resection (whether for symptomatic control or to establish pathology)

Exclusion

Exclusion criteria not yet provided.